erythromycin

erythromycin
Ed (Edgar181) · Public domain · source
Name	Erythromycin
Routes of administration	Oral, intravenous, topical, ophthalmic
Class	Macrolide antibiotic
Legal status	Prescription only

erythromycin is a macrolide antibiotic used to treat a range of bacterial infections. It is commonly employed for respiratory tract infections, skin and soft tissue infections, and as an alternative in patients allergic to penicillin. Developed in the mid-20th century, it has played a role in clinical practice alongside other agents such as penicillin, tetracycline, ceftriaxone, azithromycin, and clarithromycin.

Medical uses

Erythromycin is indicated for infections caused by susceptible organisms including Streptococcus pneumoniae, Staphylococcus aureus, Corynebacterium diphtheriae, and atypical pathogens like Mycoplasma pneumoniae and Legionella pneumophila. It is used in the management of community-acquired pneumonia, pertussis (whooping cough), erysipelas, and acne vulgaris as an alternative to agents such as minocycline and isotretinoin in selected patients. In obstetrics, erythromycin has been used for peripartum prophylaxis in specific scenarios, and for neonatal prophylaxis of ophthalmia when agents like tetracycline ointment or gentamicin are not suitable. It is also used topically in dermatology and ophthalmology, with formulations analogous to treatments developed by companies like Pfizer and GlaxoSmithKline.

Mechanism of action

Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting translocation and protein synthesis, a mechanism shared with agents such as chloramphenicol and clindamycin. Resistance mechanisms include methylation of ribosomal RNA by erm genes, active efflux mediated by mef genes, and enzymatic inactivation similar to patterns seen with other macrolide-resistant organisms studied at institutions like the Centers for Disease Control and Prevention and World Health Organization. The drug’s bacteriostatic action can be bactericidal at high concentrations or against highly susceptible species, analogous to concentration-dependent effects characterized in pharmacology research at universities such as Harvard University and Johns Hopkins University.

Pharmacokinetics

Erythromycin has variable oral bioavailability due to gastric acid degradation and first-pass hepatic metabolism via cytochrome P450 enzymes, notably CYP3A4, studied in labs at National Institutes of Health and University of Oxford. It achieves therapeutic concentrations in lung tissue, skin, and the nasopharynx, comparable in distribution studies to agents evaluated at Mayo Clinic and Cleveland Clinic. The drug is metabolized hepatically and excreted in bile, with dose adjustments considered in hepatic impairment as advised in clinical guidelines from organizations like the American College of Physicians and Infectious Diseases Society of America. Intravenous formulations bypass absorption variability but carry risks of infusion-related reactions documented in pharmacopoeias such as the British Pharmacopoeia.

Adverse effects

Common adverse effects include gastrointestinal symptoms—nausea, vomiting, abdominal pain, and diarrhea—reported in postmarketing surveillance databases maintained by regulators like the U.S. Food and Drug Administration and European Medicines Agency. Erythromycin can prolong the QT interval and has been associated with torsades de pointes in case series published in journals linked to The Lancet and The New England Journal of Medicine. Hepatotoxicity, including cholestatic hepatitis, has been reported in literature from centers such as Mayo Clinic and Johns Hopkins Hospital. Hypersensitivity reactions, though less common, are documented in clinical compendia edited at institutions like Cambridge University Press.

Drug interactions

Erythromycin is a potent inhibitor of CYP3A4 and can increase plasma concentrations of substrates including warfarin, simvastatin, midazolam, and certain calcium channel blockers; interactions have been detailed by the British National Formulary and pharmacology reviews at Stanford University. Co-administration with other QT-prolonging agents such as amiodarone, sotalol, or certain antipsychotics elevates arrhythmia risk. Drug interaction alerts and guidance are routinely issued by agencies like the MHRA and FDA.

History and development

Erythromycin was discovered in 1952 in soil samples collected in the Philippines by researchers at the pharmaceutical company Eli Lilly and Company and further developed through collaborations involving academics from University of the Philippines and industrial chemists. The compound’s isolation and structural elucidation were milestones reported in mid-20th-century chemical literature alongside discoveries like penicillin and streptomycin. Subsequent semisynthetic derivatives gave rise to later macrolides such as azithromycin and clarithromycin, with development histories chronicled in works associated with Merck and AbbVie.

Formulations and administration

Available formulations include oral tablets and suspensions, intravenous solutions, topical creams, and ophthalmic ointments produced by manufacturers including GlaxoSmithKline and Pfizer. Dosing regimens vary by indication, patient age, and formulation, with pediatric dosing often provided in liquid suspensions analogous to guidance from pediatric references like AAP. For patients unable to tolerate oral intake, intravenous administration under monitoring in hospital settings such as intensive care units is used, with stewardship recommendations from organizations like CDC and IDSA to limit resistance emergence.

Category:Macrolide antibiotics